Tibet AIM Pharm. Inc. (SHE:002826)

China · Delayed Price · Currency is CNY

15.86

+0.05 (0.32%)

Oct 23, 2026, 3:04 PM CST

Market Cap	3.01B -16.1%
Revenue (ttm)	684.45M +12.0%
Net Income	121.70M +177.6%
EPS	0.66 +176.6%
Shares Out	190.07M
PE Ratio	23.96
Forward PE	n/a
Dividend	0.15 (0.95%)
Ex-Dividend Date	Jun 9, 2026

Volume	3,254,898
Open	16.66
Previous Close	15.81
Day's Range	14.93 - 16.66
52-Week Range	14.65 - 23.19
Beta	0.35
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About Tibet AIM Pharm.

Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company’s products include Miglitol tablets for diabetes; ethnic medicine products, suitable for treating breast lobular hyperplasia, uterine fibroids, and ovarian cysts; medicines for gynecology and obstetrics; and Gualoupi injection, Nalmefene hydrochloride injection, and Carbetocin injection. It also provides Domperidone tablets for treatment of indigestion, abdominal bloating, belching, nausea, vomiting, and abdominal dis... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2003

Employees 405

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 002826

Full Company Profile

Financial Performance

In 2025, Tibet AIM Pharm.'s revenue was 636.27 million, a decrease of -2.39% compared to the previous year's 651.88 million. Earnings were 92.58 million, an increase of 101.57%.

Financial Statements